It is possible, if you lay the groundwork, to provide patients with acute leukemias with aggressive and effective therapies, while still allowing them to maintain quality of life, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Typically, patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) receive aggressive chemotherapy treatment that requires long hospital stays, but it is possible to put the foundation in place for these patients to receive support in the outpatient setting in order for them to maintain quality of life and remain close to the people who matter to them, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Transcript
Your earlier research has shown the benefits of early discharge to an outpatient setting after intensive chemotherapy for AML or MDS. Does this still hold true? And how can value-based care enhance this practice?
So that was a study that I participated in during my fellowship at the University of Washington Fred Hutch Cancer Center. And yes, I absolutely do think that its findings are relevant, primarily because the patients with acute leukemias who are eligible to receive higher doses of chemotherapy or attempt the curative therapy, still, the treatment remains the same: it's still very high doses of chemo followed often—at most institutions—by a very prolonged hospital stay. As you can imagine, this really influences the mental health and quality of life of a patient who is not only now dealing with a new very serious cancer diagnosis and the side effects of their treatment, but also become very isolated from things that they love to do on a daily basis. It becomes more difficult for them to see the people that they like to spend time with. In addition to that, it becomes very hard on the caregivers as well.
The goal of that study was to try to provide patients with equivalent, aggressive, and effective care but also allow them to improve their overall experience in the posttreatment setting. I think that is something we should always be striving to do but do it in a safe manner. As we said in the study, it was extremely important for us to have outpatient resources and supportive care, space, and providers in place in order to provide the much needed supportive therapy that they need after treatments. This should only be done with the greatest thought that goes into laying the groundwork for it ahead of time and knowing that you have the space and resources and expertise to be able to provide it.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More